Sunshine laws and the pharmaceutical industry

JAMA

Volumn 297, Issue 11, 2007, Pages 1255-1257

  Brennan, Troyen A ^a   Mello, Michelle M ^b  

^a AETNA   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG INDUSTRY; DRUG LEGISLATION; DRUG MANUFACTURE; DRUG MARKETING; EDITORIAL; HUMAN; MEDICAL ETHICS; MEDICAL FEE; MEDICAL LITERATURE; MEDICAL RESEARCH; MORBIDITY; MORTALITY; PRIORITY JOURNAL; PUBLIC HEALTH; UNITED STATES; CONFLICT OF INTEREST; ETHICS; GIFT GIVING; INTERPERSONAL COMMUNICATION; LEGAL ASPECT; NOTE; PHYSICIAN; PUBLIC RELATIONS;

CONFLICT OF INTEREST; DISCLOSURE; DRUG INDUSTRY; GIFT GIVING; INTERPROFESSIONAL RELATIONS; PHYSICIANS; UNITED STATES;

EID: 33947515619     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.297.11.1255     Document Type: Editorial

References (16)

1. Cutler DM, Rosen AB, Vijan S. The value of medical spending in the United States, 1960-2000. N Engl J Med. 2006;355:920-927.
2. Cutler DM. Your Money or Your Life: Strong Medicine for America's Health Care System. New York, NY: Oxford University Press; 2004.
3. Cutler DM, McClellan M. Is technological change in medicine worth it? Health Aff (Millwood). 2001;20:11-29.
4. Cutler DM, Long G, Berndt ER, et al. The value of antihypertensive drugs: a perspective on medical innovation. Health Aff (Millwood). 2007;26:97-110.
5. Rosen AB, Hamel MB, Weinstein MC, Cutler DM, Fendrick AM, Vijan S. Cost-effectiveness of full Medicare coverage of angiotensin-converting enzyme inhibitors for beneficiaries with diabetes. Ann Intern Med. 2005;143:89-99.
6. Harris Interactive Inc. Healthcare industries still amongst most popular targets for more regulation but support for regulation declines for third year in a row. Healthcare News. 2006;6:1-5. http://www.harrisinteractive.com/news/ newsletters/healthnews/HI_HealthCareNews2006Vol6_Iss08.pdf. Accessed November 28, 2006.
7. Brennan TA, Rothman DJ, Blank L, et al. Health industry practices that create conflicts of interest: a policy proposal for academic medical centers. JAMA. 2006;295:429-433.
8. Weintraub A. The doctor won't see you now. Business Week. 2007:30-32 February 5.
9. Ross JS, Lackner JE, Lurie P, Gross CP, Wolfe S, Krumholz HM. Pharmaceutical company payments to physicians: early experiences with disclosure laws in Vermont and Minnesota. JAMA. 2007;297:1216-1223.
10. Gifts to Physicians from Industry [Web page]. Chicago, Ill: American Medical Association. http://www.ama-assn.org/ama/pub/category/8484.html. Accessed February 21, 2007.
11. Pharmaceutical Research and Manufacturers of America. Code on interactions with healthcare professionals, 2002. http://www.phrma.org/files/ PhRMA%20Code.pdf. Accessed February 7, 2007.
12. Kesselheim AS, Mello MM. Confidentiality laws and secrecy in medical research: improving access to drug safety data. Health Aff (Millwood). In press.
13. Report on the performance of drug and biologics firms in conducting post-marketing commitment studies: availability. Fed Reg. 2007;72:5069-5070.
14. Hampson LA, Agrawal M, Joffe S, Gross CP, Verter J, Emanuel EJ. Patients' views on financial conflicts of interest in cancer research trials. N Engl J Med. 2006;355:2330-2337.
15. Engel M. A pox on drug maker freebies, say some doctors. Los Angles Times. February 4 2007:A1.
16. Nocera J. The dangers of swinging for the fences. New York Times. January 27, 2007:C1.